Biocon Biologics clears path for Stelara Biosimilar in major markets 

Biocon Biologics CEO Shreehas Tambe says Bmab 1200 will strengthen its immunology franchise, enabling it to offer an affordable and effective treatment option for patients impacted by autoimmune diseases